Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8367482 | 1.00 | BDKRB2 (0.83) | BDKRB2 | |
| Fr-173657 SCHEMBL29473494 | 0.91 | BDKRB2 (1.00) | BDKRB2 | |
| Fr-173657 SCHEMBL3718364 | 0.91 | BDKRB2 (1.00) | BDKRB2 | |
| Fr-173657 SCHEMBL1559539 | 0.91 | BDKRB2 (1.00) | BDKRB2 | |
| Fr-173657 SCHEMBL7246238 | 0.90 | BDKRB2 (0.99) | BDKRB2 | |
| Fr-173657 SCHEMBL7246230 | 0.90 | BDKRB2 (0.99) | BDKRB2 | |
| SCHEMBL8361832 | 0.89 | BDKRB2 (0.82) | BDKRB2 | |
| SCHEMBL8361829 | 0.89 | BDKRB2 (0.82) | BDKRB2 | |
| SCHEMBL7748660 | 0.89 | BDKRB2 (1.00) | BDKRB2 | |
| SCHEMBL7748662 | 0.89 | BDKRB2 (1.00) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5994368-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |